19 September 2022>: Clinical Research
Circulating Methylated DNA Analyses to Predict Recurrence Risk and Adjuvant Chemotherapy Benefit in Stage II to III Colorectal CancerZhen Yuan 12ABCEF* , Shuyuan Wang 12ABCDEF* , Kemin Ni 12ACDF* , Yixiang Zhan 12ACDF* , Hong Ma 1BDF , Xinyu Liu 13ABC , Ran Xin 2ABC , Xingyu Zhou 2BC , Zhaoce Liu 12BC , Xuanzhu Zhao 14BC , Xin Yin 2BC , Hangyu Ping 2BC , Yaohong Liu 2BC , Wanting Wang 4BC , Suying Yan 4BC , Qiurong Han 4BC , Wei Cui 5CD , Xipeng Zhang 167ADF , Qinghuai Zhang 167ABCD* , Chunze Zhang 167ABCDEFG*
Med Sci Monit 2022; 28:e937757
Figure 3 Positive detection rate of mSEPT9, CEA, CA19-9, and CA242 for patients who received adjuvant chemotherapy and subsequently suffered a radiologic recurrence (A) or remained radiological recurrence-free (B) during their surveillance. (C) The ROC curve for mSEPT9, CEA, CA19-9 and CA242. ROC, receiver operating characteristic. SPSS 26.0 (SPSS, Inc., Chicago, Illinois, USA) and PowerPoint 2018 (Microsoft, Inc., Redmond, WA, USA) were used for Figure creation.